We have a number of exciting and innovative cannabinoid research projects across several species generating the evidence needed to improve healthcare in both humans and animals. We are actively involved in, or sponsor, projects with different Universities under relevant U.K. Home Office licenses. These include ‘Seed genetics and phenomics’, ‘Fractionation’, ‘Process engineering & optimisation’, Preclinical trials into the comparative effects and efficacy of cannabinoids in the treatment of ‘Anxiety’; ‘Dependence and substance use’, ‘Infection, inflammation and immunity’ and ‘Pain and nausea’.
Peer reviewed publications will be made available in due course.
We invite enquiries from academic teams and partners who need reliable and consistent supplies of high quality Cannabinoid products manufactured utilising current ‘best practices’ found within the Active Pharmaceutical Ingredients (API) industry.
Telephone: +44 0151 482 9160
PAIN Journal, March 2021.
Summary: CB1 and CB2 agonists can reduce pain in inflammatory and neuropathic pain models wheras cannabidiol may only reduce pain behaviour in neuropathic models.
Summary: Preliminary evidence suggests that CBD reduces craving for opiates in humans.
Pubmed, February 2021.
Summary: A summary of preclinical literature on anxiolytic and antidepressant effects of cannabidiol.
JAMA Network, December 2020.
Summary: This randomised placebo controlled trial evaluated whether cannabidiol was effective in reducing the number of seizures in people with tuberous sclerosis. All participants were already taking standard treatments for epilepsy. The number of seizures was reduced by about half in people taking 25mg/kg/day of cannabidiol and by a similar amount in those taking 50mg/kg/day of cannabidiol. Common unwanted effects were diarrhoea and drowsiness which were more frequent in those taking the higher dose of cannabidiol.
Pubmed, November 2020.
Summary: Preliminary data showing efficacy and patients preferred the formulation to placebo.
Nature Research, Molecular Psychiatry, October 2020.
Summary: This paper gives further details about the mechanisms by which endocannabinoids may regulate mood.
Pubmed, National Library of Medicine, October 2020.
Summary: This case report describes a 20 year old man with social anxiety disorder and attenuated psychotic symptoms which had not responded to conventional treatment with antidepressants and psychological therapy. The man experienced symptom relief when treated with cannabidiol in doses between 200 and 800 mg/day for 6 months.
Journal of Transnational Medicine, October 2020.
Summary: This recent overview provides a summary of all studies to date in humans and animals where cannabis extracts, THC and CBD have been investigated for their effects on anxiety.